Compare Corning Incorporated (GLW) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corning Incorporated vs BIO-TECHNE Corp — how do they compare? Corning Incorporated trades at $159.82 (market cap $135.89B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Corning Incorporated is far larger — about 12.1× BIO-TECHNE Corp's market cap, and Corning Incorporated pays the higher dividend (0.71%). Which is the better fit depends on your goals.
| GLW | TECH | |
|---|---|---|
Market Cap | $135.89B | $11.24B |
Sector | Technology | Health |
52-Week High | $255.79 | $72.29 |
52-Week Low | $64.52 | $43.31 |
Enterprise Value | $142.77B | $11.32B |
Dividend Yield | 0.71% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GLW trades at $165.69, up 5.41% today, with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. Revenue grew to $15.63B in 2025, with net income surging to $1.60B. The stock is supported by AI-driven optical demand and analyst optimism, though valuation multiples like a P/E of 76.35 appear elevated. Recent news highlights partnerships with major tech firms and a strategic focus on photonics expansion.
The outlook for GLW is positive, driven by AI infrastructure growth and a $10B photonics goal, but risks include high valuation sensitivity and execution challenges. Analysts project a 16.6% upside to the $193.33 consensus target, with 57% recommending buy. Investors should weigh robust fundamentals against premium pricing and competitive pressures in the semiconductor supply chain.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Corning Incorporated
Corning Inc is a leader in materials science, specializing in the production of glass, ceramics and optical fiber. The firm supplies its products for a wide range of applications, from flat-panel displays in televisions to gasoline particulate filters in automobiles to optical fiber for broadband access, with a leading share in many of its end markets.
Read more on GLW →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
